Neil Kumar sold $3.7M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 44,980 shares at an average of $82.86, traded Aug 18, 2026, filed Aug 20, 2026.
Score components
- +25RoleCEO
- +25Trade size$3.7M at market
- +5Share of holdings soldSold 16% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-26-000848, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | SOpen-market sale Common Stock10b5-1 | -1,900 | $81.15 | $154k | 276,407 | Aug 20, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stock10b5-1 | -17,279 | $82.21 | $1.4M | 259,128 | Aug 20, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stock10b5-1 | -14,602 | $82.99 | $1.2M | 244,526 | Aug 20, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stock10b5-1 | -1,199 | $83.77 | $100k | 243,327 | Aug 20, 2026 |
| Aug 19, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -8,100 | $83.86 | $679k | 507,586 | Aug 20, 2026 |
| Aug 19, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -1,800 | $84.69 | $152k | 505,786 | Aug 20, 2026 |
| Aug 19, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -100 | $85.65 | $8,565 | 505,686 | Aug 20, 2026 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 6Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $160k 2,000 shares | -2% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $13M 148,589 shares | -95% | |
| 23Weak | BridgeBio Pharma, Inc. | Andrea Ellis director | $1.4M 17,167 shares | -43% | |
| 13Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $342k 5,004 shares | -35% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $2.8M 39,363 shares | -372% | |
| 40Moderate | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $6.0M 90,240 shares | -93% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -14% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.8M 26,103 shares | -10% | |
| 25Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $671k 10,000 shares | -46% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.